In addition, the SUMMIT trial evaluates the effect of tirzepatide (the GLP-1/GIP dual receptor agonist) in people with obesity-related HFpEF (Clinicaltrials.gov ID NCT04847557)
doi: 10.1002/eji.1830261229
Sameer Murali, MD, Medical Director of Obesity Medicine at Memorial Hermann Health System in Houston, Texas, explains that patients should expect a nearly identical effectiveness and safety profile compared to the name brand. They both come in the same forms and dosages, theyre taken the same way, and they both contain the same active ingredient, liraglutide
How this compares to other DIM products Popularity Top 10% DIM products Trending +50% Compared to last 30 days Quality rank High Higher TrustScore than 93% of DIM products Cost rank Average More affordable than 36% of DIM products Loading related products
Front Endocrinol (Lausanne), 2021